<DOC>
	<DOCNO>NCT01923597</DOCNO>
	<brief_summary>The purpose study determine safety effect green tea ( epigallocatechin gallate ) albuminuria diabetic patient nephropathy .</brief_summary>
	<brief_title>Effect Green Tea ( Epigallocatechin Gallate ) Albuminuria Patients With Diabetic Nephropathy .</brief_title>
	<detailed_description>Clinical , prospective , randomize , double-blind , placebo-controlled , analysis intention treat . 50 individual select diagnosis diabetes / hypertension follow Diabetic Nephropathy Clinic Faculty Medical Sciences , University Campinas ( UNICAMP ) . Participants divide 02 group : 1 ) 25 patient treated maximum dose ACE-I / angiotensin II receptor blocker ( ARBs ) + Placebo ( absence epigallocatechin gallate ) 2 ) treat 25 patient maximum dose ACE-I / ARBs + green tea ( epigallocatechin gallate ) . The patient receive four capsule Polyphenol E - epigallocatechin gallate ( Polyphenon Pharma , NY ) per day , correspond 800 mg epigallocatechin gallate ( EGCG ) , placebo ( epigallocatechin gallate ) 3 month . Patients aware treatment receiving . The subject allocate treatment placebo , stratify sex . To avoid influence researcher , randomization list generate maintain trained personnel different location study . Before treatment immediately 3 month treatment obtain primary outcome measure ( albuminuria ) secondary ( plasma metabolite flavonoid , level urinary F2-isoprostane 8-hydroxydeoxyguanosine ) . In time obtain : blood biochemistry ( glucose , glycosylated hemoglobin , urea , creatinine , sodium , potassium , blood count , calcium , phosphorus , cholesterol , LDL , HDL , triglyceride , uric acid ) , 3 sample first morning urine determine albuminuria , glomerular filtration rate ( GFR ) , blood pressure measurement 24 h , physical examination , weight , blood pressure heart rate . Adherence study evaluate weekly phone expect increase plasma flavonoid use green tea ( epigallocatechin gallate ) . The antihypertensive drug may adjust obtain desired pressure ( &lt; 130/80 mmHg ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>18 year prior diagnosis diabetes mellitus ( DM ) persistent microor macroalbuminuria ( urinary albumin excretion &gt; 30 mg / g creatinine ( AUC ) 3 consecutive measurement different day ) glycated hemoglobin &lt; 10 % maximum dose ACEI / ARBs . diagnosis autoimmune disease , HIV , hepatitis , cancer , inflammatory disease pregnant lactating patient glomerular filtration rate ( GFR ) &lt; 30 ml/min/1 , 73m2 ( estimate MDRD CockcroftGault formula ) presence kidney disease unrelated diabetes chronic urinary tract infection diagnosis congestive heart failure ( CHF ) New York Heart Association ( NYHA ) class III IV recent history ( &lt; 6 month ) unstable angina , myocardial infarction , stroke , coronary intervention history alcohol / drug mental incapacity understand inform consent intolerance green tea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Proteinuria</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Epigallocatechin gallate</keyword>
</DOC>